Skip to main content

05 July 2022

How Scalable Manufacture will Enable Progress for Lentiviral Therapies

Katie Roberts

Editorial /International Biopharmaceutical Industry/05 July 2022

Download PDF – 442.7 KB


In the twenty years since creation of the first effective CAR-T cells, lentiviral vectors have become valuable tools for the development of ex vivo gene and cell therapies. Two ex vivo lentiviral gene therapy products have recently reached the market, one approved for treatment of acute lymphoblastic leukaemia and the other for beta thalassemia. The successful development of these treatments has demonstrated the potential for lentiviral therapies to treat cancer and other diseases.

Download the resource to continue reading.